Screener
Spyre Therapeutics, Inc. SYRE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
FAQ
- What is Spyre Therapeutics, Inc.'s EPS (diluted)?
- Spyre Therapeutics, Inc. (SYRE) reported EPS (diluted) of -$0.74 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Spyre Therapeutics, Inc.'s EPS (diluted) decreased by 23.3% year-over-year, from -$0.60 to -$0.74.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s EPS (diluted) has grown at a -57.1% compound annual growth rate (CAGR), from -$25.02 to -$1.98.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Spyre Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude